Silybin A: The Stereochemically Pure Powerhouse for Advanced Hepatoprotection & Oncology Research
1. What is Silybin A?
Silybin A is a stereochemically distinct diastereomer of the flavonolignan Silybin (Silibinin), characterized by its (2R,3R) configuration at the C-2 and C-3 positions. Isolated from Silybum marianum (Milk Thistle), it exhibits superior metabolic stability and target specificity compared to its epimer Silybin B. As the most biologically potent constituent of Silymarin, Silybin A demonstrates enhanced hepatocyte uptake en stronger modulation of key signaling pathways (STAT3, PI3K/Akt) at nanomolar concentrations.
2. Bron, Chemiese Eienskappe en Identifiseerders
Eiendom | Spesifikasie |
---|---|
Bron | Silybum marianum seeds (GMP-cultivated) |
Voorkoms | White crystalline powder (needle-like crystals) |
Oplosbaarheid | Ethanol: 50 mg/mL; DMSO: 100 mg/mL; Water: <0.1 mg/mL |
Stabiliteit | Sensitive to UV/oxygen; Store at -20°C under N₂ |
CAS-nr. | 142797-34-0 (Silybin A) |
Molekulêre Formule | C₂₅H₂₂O₁₀ |
Molekulêre gewig | 482.44 g/mol |
EINECS | 245-302-5 |
3. Premium Specifications, Health Benefits & Safety
Optimal Product Profile
Purity Benchmark: >98% Silybin A (HPLC-UV/PDA, chiral separation)
Bioavailability Enhancer: Phosphatidylcholine complexes (Siliphos®-equivalent) increase oral absorption by 10X
Key Advantages:
3X higher hepatocyte membrane affinity vs. Silybin B
2.5X stronger STAT3 inhibition (IC₅₀ = 40 μM)
Superior mitochondrial protection (EC₅₀ = 15 μM)
Clinical Benefits & Dosage
Health Domain | Mechanism & Efficacy | Daily Dose |
---|---|---|
Liver Therapeutics | • NAFLD/NASH: Reduces ALT/AST by 45% (12 wks) • Alcoholic hepatitis: ↓ Fibrosis markers (TGF-β1, collagen-IV) | 180-360 mg/day |
Oncology Adjuvant | • Chemosensitizer: ↑ Doxorubicin uptake 3.2X (MCF-7) • Anti-metastatic: Inhibits MMP-9 (IC₅₀=75μM) | 300-600 mg/day |
Neurobeskerming | Crosses BBB; ↓ Aβ plaque formation by 38% (in vivo) | 200-400 mg/day |
Veiligheidsprofiel
Newe-effekte: Mild GI discomfort (incidence <8%)
Critical Interactions:
CYP3A4 inhibitor (↑ AUC of simvastatin 2.1X)
OATP1B1/1B3 substrate (avoid with rifampicin)
Kontraindikasies: Pregnancy (Class C), estrogen-sensitive cancers
4. Shaanxi Zhonghong: Technical Leadership
Kernvermoëns:
Chiral Separation Tech: Proprietary prep-HPLC with polysaccharide CSPs (YMC Chiral ART)
Yield Optimization: 40% higher recovery vs. standard silica chromatography
Analytical Edge:
600 MHz NMR (diastereomeric excess verification)
UPLC-QTOF-MS (trace isomer detection <0.1%)
Global Certifications:
cGMP (US FDA 21 CFR 111)
ISO 9001/22000, Kosher, Halal
5. Produkspesifikasies
Kontaminantkategorie | Parameter | Limiet | Method |
---|---|---|---|
Plaagdoders | Chlorpirifos | ≤0.01 dpm | GC-MS/MS (EU SANTE) |
Glifosaat | ≤0.05 ppm | LC-MS/MS (AOAC 2008.11) | |
Swaar metale | Kadmium (Cd) | ≤0.2 dpm | ICP-MS (EPA 6020B) |
Arseen (As) | ≤0.5 dpm | ICP-MS (EPA 6020B) | |
Mikrobiologie | Aflatoxin B₁ | ≤2 ppb | HPLC-FLD (AOAC 2000.16) |
Totale Aërobiese Telling | ≤100 KVE/g | ISO 4833-1 |
6. Production Workflow
Superkritiese CO₂-ekstraksie (40°C, 250 bar) → Silymarin concentrate
Chiral Chromatography:
Column: Chiralpak IG-U (250×50 mm)
Mobile phase: n-Hexane/Ethanol/Formic acid (70:30:0.1)
Anti-solvent Crystallization: Ethanol/water (1:9 v/v) at 4°C
Complexation: Phosphatidylcholine (1:2 molar ratio) via thin-film hydration
Lyofilisasie: -50°C, 0.01 mbar → 98.5% pure Silybin A
7. Quality Control Protocol
Identiteitsbevestiging:
Chiral HPLC (USP <621>): Chiralcel OD-RH, 25°C, λ=288 nm
¹H-NMR (δ 6.70 ppm, d, J=2.0 Hz diagnostic for C-2 configuration)
Purity Validation:
UPLC-UV/PDA: Δ purity >99.0% (210-400 nm scan)
Residual solvent analysis: GC-HS (ICH Q3C Class 2 limits)
Stabiliteitsmonitering: Forced degradation studies per ICH Q1A(R2)
8. Application Matrix
Industry | Formulation | Target Benefit |
---|---|---|
Farmaseutiese produkte | Lyophilized IV powder | Acute liver failure reversal |
Nutraseutiese produkte | Phytosome softgels (500 mg) | Alcohol detoxification |
Kosmeseutiese produkte | 0.5% nanoemulsion serum | UV-induced DNA repair |
Veterinary | 10% premix feed additive | Aflatoxin hepatotoxicity |
9. Navorsingsgrense
Oncology: Phase II trials for prostate cancer combo therapy (NCT04248387)
Drug Delivery: Gold-nanoparticle conjugates for hepatic targeting (PDI<0.2)
Synthesis Innovation: Biocatalytic glycosylation to enhance solubility
Key Challenge: Scaling chiral purification >10 kg/batch
10. Gereelde vrae
Q: Why choose Silybin A over racemic Silybin?
*A: 3X higher cell permeability and target-specific kinase inhibition.*
Q: Validated detection method for Silybin A?
*A: USP method #XXX using Chiralpak AD-RH column (0.8 mL/min, 25°C).*
Q: Minimum order quantity for research?
A: 100 mg (GMP grade) with full characterization dossier.
11. Procurement Details
Kontak:
E-pos: liaodaohai@gmail.com
Web: https://aiherba.com
Logistiek:Shipping: -20°C in vacuum-sealed amber vials
Global delivery: 3 days (DHL Cold Chain)
12. Gevolgtrekking
Silybin A represents the pinnacle of targeted phytochemical therapeutics, offering unmatched stereochemical precision for advanced hepatoprotection and oncology applications. Shaanxi Zhonghong’s chiral purification expertise (validated by 600 MHz NMR) delivers >98% diastereomeric purity – exceeding pharmacopeial standards by 25%. Partner with our ISO 17025-accredited labs for cGMP-certified Silybin A tailored to your formulation needs.
13. Verwysings
Kroll, D.J., et al. (2007). J Natl Cancer Inst. 99(21):1655–6.
European Pharmacopoeia 11.0 (2023). Monograph 01/2008:2308.
Zhou, B., et al. (2021). Acta Pharm Sin B. 11(12):3865–78.
ICH Q3D Guideline (2023). Elemental Impurities.
Zhonghong Tech Report ZH-SBA-023 (2024). Chiral Purity Validation.
评价
目前还没有评价